This Stock Could Rise Over the Next 10 Years

Neovasc Inc. (TSX:NVCN)(NASDAQ:NVCN) is seeking strategic alternatives and alliances to build on the growing enthusiasm in the market for the company’s products.

| More on:

Neovasc (TSX:NVCN)(NASDAQ:NVCN) is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. The company’s products include Neovasc Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States, and the Tiara for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the U.S., Canada, Israel, and Europe.

The company’s core strategy is to focus on establishing confidence with Neovasc’s stakeholders, and to continue the development and commercialization of the company’s products. Through the Tiara and the Reducer, Neovasc is working on providing minimally invasive medical devices for a cardiovascular market that the company believes is both growing and underserved by current treatment solutions. Neovasc was incorporated in 2000 and is headquartered in Richmond, Canada.

Treatment of refractory angina

With regards to the Reducer, the company is continuing therapy development and has successfully supplemented a clinical study with additional clinical experience. Neovasc is targeting a commercial launch in Europe. Improving revenue growth in Europe and providing reimbursement initiatives in other international markets could significantly increase the company’s stock price.

Neovasc is also seeking strategic alternatives and alliances to build on the growing enthusiasm in the market for the Reducer in order to broaden and deepen therapy penetration in Europe and the Middle East. The company is evaluating several studies with U.S. Food and Drug Administration (FDA) and approvals could result in a sales boost for Neovasc.

Treatment of mitral valve disease

The company’s clinical experience of the Tiara was successful, and the clinical data study was used by the company to file for commercialization. Enrollment in the clinical study was closed in 2019 with a total of 27 patients being treated for the next five years. The company is targeting a European regulatory decision for Tiara in the first half of 2021, although it provides no assurance that European regulatory approval will be granted in the time frame anticipated by management or granted at any time in the future. If the development of the Tiara system for preclinical bench and animal studies leads to successful completion, this could be followed by human compassionate use in the second half of 2021.

Robust product pipeline

Product development activities have recently started at the company for the development of the Tiara system, focused on a suitable and novel transfemoral delivery system. Further, the company is working on few important but minor changes to the Tiara valve to make it deliverable and to further penetrate the patient population. These development activities are taking place at the company’s Vancouver facility. Furthermore, engineering resources are continuing to support manufacturing for both the Reducer system, and the Tiara system for clinical studies.

Neovasc’s specialty medical devices products could have a revolutionary impact on the cardiovascular industry in Europe, Canada, the U.S., and internationally. The company’s Tiara technology is likely to be widely used for the transcatheter treatment of mitral valve disease. Further, Neovasc’s Reducer is also to be likely used for the treatment of refractory angina in the future.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

Young woman sat at laptop by a window

SPY Stock Is Just the Tip of the Iceberg for Canadians Investing in the U.S.

These two BMO ETFs are great alternatives to just buying SPY.

Read more »

TFSA and coins
Stocks for Beginners

How a BIG New TFSA Change Could Affect You in 2024

Canadians are in for a BIG surprise for the TFSA in 2024. Here's how TFSA changes could help you keep…

Read more »

Growing plant shoots on coins
Dividend Stocks

2 Under-the-Radar Dividend Payers With Solid Growth Prospects in 2024

These under the radar monthly dividend payers could provide good growth prospects in 2024 and beyond.

Read more »

Bank Stocks

3 Reasons I’m Buying Royal Bank Stock Today

Royal Bank (TSX:RY) stock has shown signs of strength and yet still put aside $720 million in provisions for loan…

Read more »

Business success with growing, rising charts and businessman in background
Tech Stocks

Growth Stocks: A Once-in-a-Lifetime Opportunity to Get Rich

Here's why investing in quality growth stocks such as Docebo and Datadog may allow you to generate sizeable returns.

Read more »

Question marks in a pile
Dividend Stocks

Should You Buy BMO Stock for its 5.2% Dividend Yield?

BMO stock has outpaced the broader markets in the past two decades. But is this blue-chip TSX bank stock a…

Read more »

Mature financial advisor showing report to young couple for their investment
Bank Stocks

3 Top Financial Stocks to Buy on the TSX Today

The top financial stocks to buy on the TSX today are two small lenders and one Big Bank.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Corp: Will it Ever Be a Buy?

Canopy Growth Corp (TSX:WEED) keeps going lower. Will it ever find a bottom?

Read more »